WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, a clinical-stage biotechnology company creating a new class of drugs based on small molecule stimulation of dormant stem cells within the body which we refer to as Progenitor Cell Activation (PCA), today announced that the Company will present a podium presentation at the upcoming 42nd Annual Mid-Winter Meeting of the Association for Research in Otolaryngology (ARO) in Baltimore, MD, taking place February 9-13, 2019.
Will McLean, Ph.D., Co-Founder and Vice President of Biology and Regenerative Medicine at Frequency, will discuss new research highlighting activation methods and the molecular underpinnings that drive cochlear cell proliferation and regenerative behavior. Dr. McLean will also co-moderate the Regeneration I session during the conference which will take place on Monday, February 11 beginning at 10:30am ET.
Presentation details are as follows:
Title: Lgr5+ Cochlear Progenitor Cell Proliferation is Driven by the Combined Activation of the Wnt, NonCanonical Notch, and PI3K Pathways
Abstract: PD 67
Date: Monday, February 11, 2019
Time: 11:00 – 11:15am ET
Location: Baltimore Marriott Waterfront
ABOUT PCA REGENERATION
Founded by pioneers in the field of regenerative medicine and drug delivery technology, Frequency’s Progenitor Cell Activation (PCA) Regeneration platform uses a combination of small molecules to stimulate progenitor cells within the body to repair diseased or damaged tissue. This technology enables native tissue regeneration without modifying genes or removing cells from the body. This avoids the potential safety risks of genetic engineering and the manufacturing challenges of traditional cell therapy. This approach has been validated both in animal and human cell models as well as in a human clinical trial with the potential for broad application across many therapeutic areas.
ABOUT FREQUENCY THERAPEUTICS
Frequency Therapeutics develops small molecule drugs to stimulate cells in the body to reverse biological deficits and restore healthy tissue. Through the transitory activation of these cells, Frequency enables disease modification without the complexity of genetic engineering. Our ground-breaking therapy uses a proprietary combination of small-molecule drugs that induce progenitor cells to multiply and create new cells. While Frequency’s lead program targets hearing restoration, our PCA Regeneration platform has the potential to touch upon a wide breadth of disease indications. www.frequencytx.com.
